PureTech Health (PureTech Health) Debt-to-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is PureTech Health Debt-to-Asset?

PureTech Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.09 Mil. PureTech Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.25 Mil. PureTech Health's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $693.97 Mil. PureTech Health's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

PureTech Health Debt-to-Asset Historical Data

The historical data trend for PureTech Health's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Debt-to-Asset Chart

PureTech Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.08

0.06

0.07

0.04

PureTech Health Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.06	0.06	0.07	0.04	0.04

Competitive Comparison of PureTech Health's Debt-to-Asset

For the Biotechnology subindustry, PureTech Health's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where PureTech Health's Debt-to-Asset falls into.

PureTech Health Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

PureTech Health's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.093	+	18.25)	/	693.973
	=	0.04

PureTech Health's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.093	+	18.25)	/	693.973
	=	0.04

PureTech Health (NAS:PRTC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

PureTech Health Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of PureTech Health's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (PureTech Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (NAS:PRTC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PTCHF:USA PRTCl:UK PRTC:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.